Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
about
Molecular testing to optimize therapeutic decision making in advanced colorectal cancerRecent applications of chemosensitivity tests for colorectal cancer treatmentDegradation Rate of 5-Fluorouracil in Metastatic Colorectal Cancer: A New Predictive Outcome Biomarker?ERCC1, XRCC1 and GSTP1 Single Nucleotide Polymorphisms and Survival of Patients with Colon Cancer Receiving Oxaliplatin-Based Adjuvant Chemotherapy.MTHFR, MTR, and MTRR polymorphisms in relation to p16INK4A hypermethylation in mucosa of patients with colorectal cancerPolymorphisms in folate-metabolizing enzymes and response to 5-fluorouracil among patients with stage II or III rectal cancer (INT-0144; SWOG 9304).The ERCC1 N118N polymorphism does not change cellular ERCC1 protein expression or platinum sensitivityERCC1 and ERCC2 polymorphisms predict clinical outcomes of oxaliplatin-based chemotherapies in gastric and colorectal cancer: a systemic review and meta-analysis.Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis.Association between the ERCC1 rs11615 polymorphism and clinical outcomes of oxaliplatin-based chemotherapies in gastrointestinal cancer: a meta-analysisSystematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy.ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese.Predictive diagnostics in colorectal cancer: impact of genetic polymorphisms on individual outcomes and treatment with fluoropyrimidine-based chemotherapy.Detecting KRAS mutations in peripheral blood of colorectal cancer patients by peptide nucleic acid clamp PCRA multi-center phase Ib study of oxaliplatin (NSC#266046) in combination with fluorouracil and leucovorin in pediatric patients with advanced solid tumors.Tumor site- and stage-specific associations between allelic variants of glutathione S-transferase and DNA-repair genes and overall survival in colorectal cancer patients receiving 5-fluorouracil-based chemotherapyIdentification of risk factors for recurrence in high-risk stage II colon cancerPrognostic and predictive impact of DNA mismatch repair in the management of colorectal cancer.GALNT14 Genotype Predicts Postoperative Outcome of Stage III Colorectal Cancer With Oxaliplatin as Adjuvant Chemotherapy.Association of single nucleotide polymorphisms in MTHFR and ABCG2 with the different efficacy of first-line chemotherapy in metastatic colorectal cancer.Building personalized treatment plans for early-stage colorectal cancer patients.Biomarker-based selection of therapy for colorectal cancer.Pharmacogenetics of chemotherapy efficacy in breast cancer.XRCC1 and GSTP1 polymorphisms and prognosis of oxaliplatin-based chemotherapy in colorectal cancer: a meta-analysis.X-ray repair cross-complementing 1 polymorphism and prognosis of platinum-based chemotherapy in gastric and colorectal cancer: a meta-analysis.Nucleotide excision repair and response and survival to chemotherapy in colorectal cancer patients.Concordance of genotype for polymorphisms in DNA isolated from peripheral blood and colorectal cancer tumor samples.Pharmacogenetic markers of toxicity for chemotherapy in colorectal cancer patients.Pharmacogenomics in colorectal cancer: a genome-wide association study to predict toxicity after 5-fluorouracil or FOLFOX administration.Pharmacogenetic analysis of adjuvant FOLFOX for Korean patients with colon cancer.DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer.Polymorphisms of caspase 8 and caspase 9 gene and colorectal cancer susceptibility and prognosis.
P2860
Q26749012-91F7689D-F30E-4269-A81E-917F4B164579Q26851075-064D5A0C-A532-42EB-880D-F8CB52772DB9Q28554294-6E273A4E-A2AA-405A-80AF-63CBEECDBEC0Q33634975-4F4E4781-3158-4862-86F8-9F6B3545B18DQ34112730-C8E31236-F73C-449B-B28B-933178A40F9DQ34653433-FA8FFDD0-6130-49E8-9D9B-83DCC0345FEDQ34676948-AF60377C-D052-44F3-A004-173782890C16Q34694410-39D26A2E-D914-4DB3-B0B4-BC198F311510Q35109800-A4A58416-582A-40BC-ABD5-3C16F35C3DF6Q35194655-4EC449D7-3220-4674-B914-B916822FB91CQ35224176-C5B5B4F8-4B86-49D7-A2B9-9DAE09C3C832Q35929617-A5F56AD3-5978-457C-8398-E7ACCA2CE8ECQ36117701-E8F69DE9-7E57-4429-BC03-D806CB7F6B08Q36385034-B64D1D0C-B3EA-4E03-8B88-B9688A5A3C1FQ36467960-4E576C1D-7109-4E3F-A688-F9FE8E1CB0AFQ37039153-6DCAB1FF-CCAA-4F91-8169-6BFCD953971EQ37044768-A5F20789-9A0E-4C85-9DCC-CAE8816243C8Q37165280-8333FEAB-7E89-4B8A-A3F6-818EF03DF74CQ37206438-E09B719F-02D3-41DB-9816-58C8EC5A1263Q37471631-2E48B6CA-6420-45BF-94C7-6F6E0B3000DCQ37706705-C2432D0D-35BB-40C9-8B70-25CEE0C93CDDQ37886995-24A99B6A-B064-4734-A54C-3926982EC33DQ38003703-47FB1A2E-D05D-4EE1-B703-1537F6F6DCEEQ38072637-C638F602-0FB6-4976-8723-B91E48916E14Q38162285-F7D421DE-9443-490F-A493-3EFD73B39AE2Q38835268-127FC53E-4C46-4B38-B3DA-54D2654EB396Q39307013-75761CA3-A892-4AF9-934F-4C9E947F8B4EQ39566084-D7F61359-A3B3-4AAF-A194-C3B62112813AQ43986380-FB2138A1-024B-46DF-A3EE-B502309EF7E5Q44661317-C162A993-36B9-4A38-AC27-9E8E3BE160A1Q48310481-3F0C72A5-78B6-4E48-8B29-986DB681D82CQ54374974-F75DCCB4-6412-4D24-860D-AD8122EE04EF
P2860
Molecular markers of response and toxicity to FOLFOX chemotherapy in metastatic colorectal cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Molecular markers of response ...... metastatic colorectal cancer.
@en
Molecular markers of response ...... metastatic colorectal cancer.
@nl
type
label
Molecular markers of response ...... metastatic colorectal cancer.
@en
Molecular markers of response ...... metastatic colorectal cancer.
@nl
prefLabel
Molecular markers of response ...... metastatic colorectal cancer.
@en
Molecular markers of response ...... metastatic colorectal cancer.
@nl
P2093
P2860
P356
P1476
Molecular markers of response ...... n metastatic colorectal cancer
@en
P2093
P2860
P2888
P304
P356
10.1038/SJ.BJC.6605239
P407
P577
2009-08-11T00:00:00Z